Artikel

17 Aug 2006

Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

[identifies pharmaceutical best practice in key areas including research, paediatric needs, drug accessibility, reporting, philanthropy, political engagement; rates 15 top pharmaceutical firms on each practice: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Zeitleiste

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Datum:

4 Mär 2014

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Datum:

30 Nov 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Datum:

13 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Datum:

12 Sep 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Datum:

6 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Datum:

6 Sep 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Reclaman mayor compromiso de las farmacéuticas

Datum:

31 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Datum:

23 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Datum:

17 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Datum:

17 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Datum:

14 Aug 2006

Inhaltsart:

Artikel

Verfügbare Sprachen: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Datum:

1 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Datum:

1 Aug 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Datum:

8 Jan 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Datum:

8 Jan 2006

Inhaltsart:

Unternehmensantwort

Verfügbare Sprachen: English

Vollständige Story anzeigen

Mehr laden Weniger anzeigen

Business & Human Rights
Resource Centre

Kontakt (Impressum)

Business & Human Rights Resource Centre

Kontakt (Impressum)

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Zeitleiste

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.